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Proton pump inhibitors (PPIs) are among the most frequently prescribed drugs 
globally. While they are highly cost-effective when used appropriately, studies 
across a wide range of populations continue to identify that they are prescribed 
without a clear indication in up to 70% of cases. This results in a cost to the NHS 
in excess of £100m each year1. In addition, although the absolute risk of harm to 
individuals from PPIs is low, their widespread long-term use is accompanied by a 
number of adverse effects that contribute significant negative impacts at a 
population level. Action is now required to limit the inappropriate prescribing of 
PPIs, and support deprescribing in patients on long-term therapy in whom the 
original indications no longer apply. 
 
The rise of PPIs 
PPIs were introduced in the 1980s, and rapidly became some of the best-selling 
medicines of all time. They inhibit gastric acid secretion through blockade of 
H+/K+-ATPases in parietal cells, and are highly effective for treating peptic 
ulceration, oesophagitis and gastro-oesophageal reflux2,3. They are also 
important components of Helicobacter pylori eradication regimens4, and useful 
for prophylaxis against non-steroidal anti-inflammatory drug (NSAID) induced 
upper gastrointestinal injury5. For most of these presentations, they are only 
intended for short-term use and rarely required beyond four to eight weeks. In a 
minority of conditions (for example, severe Barrett’s oesophagus, gastrinoma 
and eosinophilic oesophagitis), protracted courses may be required6.  
 
PPIs combine high efficacy with low toxicity, and are perceived to be safe and 
cost-effective1. Consequently, they are widely prescribed. Their use costs the 
NHS over £100m, and global spend is in excess of £2bn. Five PPIs are currently 
licensed in the UK: omeprazole, lansoprazole, pantoprazole, esomeprazole and 
rabeprazole. In most scenarios, there is no clear evidence to support use of one 
over another, and class effects can be assumed7.  
 
Overprescribing is the norm 
Studies consistently find that PPIs are overprescribed, globally, in both primary 
and secondary care. Their prevalence continues to increase: in Australia, 
prescriptions rose by 1318% over one decade8. Most of this occurs in primary 
care, with increasing numbers treated for longer durations9. Part of this relates 
to substitution of histamine-2 receptor antagonists, but the bulk represents 
expanded use of acid suppression therapy. A proportion of this increase will be 
legitimate, due to rising groups of patients treated with dual antiplatelet therapy 
for coronary artery or cerebrovascular disease, or bisphosphonates (for which 
PPIs partially mitigate risk of oesophagitis10). There is also a small cohort of 
patients with chronic cough in whom gastro-oesophageal reflux is believed to be 
a contributor11. The recent approvals of esomeprazole for general sale, and 
pantoprazole as an over-the-counter medicine, may further drive consumer use 
in the UK. 
 
A number of studies have examined the appropriateness of PPI prescriptions. In 
one series looking at medicines in elderly patients in Italy, 30% were receiving a 
PPI with no clear indication, although a further 11% of this cohort possessed a 
recognised indication and were not on treatment (that is, PPIs were 
underprescribed)12. A study of 124,133 first-time adult users from Denmark 
found that only one-third met criteria for potential long-term use, and that there 
were significant variations in initiating such therapy related to both patient and 
prescriber characteristics13. In contrast, in the same catchment population, only 
4% of pre-existing long-term users (defined as more than 60 daily doses over a 
six-month period) had a diagnosis that overtly merited such management14.  
 
Within hospitals, a retrospective study of surgical inpatients from The 
Netherlands identified non-compliance with guidelines in 46.6%; 93.1% of these 
represented overprescribing15. Audits of medical inpatients in the UK show 
inappropriate prescribing rates of 40.7–54%, of which 86% are 
overprescribing.16,17 Data from other countries are comparable, associated with 
substantial costs8,18-21.  
 
A number of studies have probed the underlying rationales for PPI prescription 
and their continued use22-24. The reasons are frequently questionable, and 
adherence to guidelines poor with behaviour challenging to adapt despite 
educational and stewardship strategies25. The most common explanations were 
inappropriate treatment of dyspepsia, prophylaxis for low-risk patients on 
NSAIDs or corticosteroids, and stress ulcer prophylaxis (in secondary care).  
 
Communication is poor. In one UK centre, suggested duration of treatment was 
specified in fewer than 20% of hospital discharge letters, less than one-third 
indicated that prescriptions needed to be reviewed, and only half contained 
information as to why the drug was started26.  
 
Overprescribing is more common in those with increasing numbers of co-
morbidities and polypharmacy, likely due in part to a belief that PPIs have 
greater benefits and safety profiles than have actually been demonstrated. 
Additionally, patients receiving multiple medicines are likely to see several 
specialists. This increases the chance of a drug being prescribed and renders it 
less likely that one clinician takes overall responsibility for the therapeutic 
repertoire or questions a prescription from a colleague. A number of cognitive 
biases come into play, including a preference to maintain the status quo, and fear 
of criticism should harm arise because of a perceived (if justified) omission27. 
 
One further specific problem is that, once a patient has taken a PPI for any more 
than a few weeks, acid hypersecretion can occur on discontinuation. This causes 
rebound symptoms, and frequently establishes a vicious cycle of drug 
reinitiation and long-term continuation28. 
 
Harms of PPI therapy 
Over the past decade, a range of adverse effects from PPI therapy have been 
identified. Although most studies are retrospective, a signal has evolved that 
PPIs are not as benign as originally perceived. Most of these translate into small 
absolute risks at an individual level, but because of prevalence and chronic use 
contribute substantial population attributable risk. 
 
The most widely studied and publicised of these is Clostridium difficile infection. 
A meta-analysis of 23 cohort and case-control studies, involving almost 300,000 
patients, identified a 65% increase in the relative risk of C. difficile-associated 
diarrhoea29. The mechanism remains unproven, but may be that acid 
suppression permits viability of the C. difficile vegetative state, subsequently 
leading to clinically symptomatic infection. There are suggestions that PPIs also 
increase risks of Campylobacter and Salmonella gastroenteritis (both are acid-
sensitive organisms)30, and two recent studies demonstrate alterations in the gut 
microbiome31. 
 
PPIs have been provisionally associated with increased risk of pneumonia (odds 
ratio on meta-analysis 1.27%)32. The proposed mechanism relates to acid 
suppression permitting gastric bacterial overgrowth, leading to respiratory tract 
infection through reflux and micro-aspiration. The caveat is that most data 
derive from retrospective studies, and at least one prospective study failed to 
verify the association33.  
 
Increased fracture risk has been reported, most notably in the Nurses Health 
Study, which included 79,899 female participants followed for eight years34. The 
age-adjusted hazard ratio of hip fracture was 1.35 with more than 2 years of PPI 
use, and even higher in smokers. Possible explanations include reduced calcium 
absorption35, or competition with osteoblast and osteoclast proton pumps that 
impedes bone remodelling36. Deficiencies have also been reported in both iron37 
and vitamin B1238 absorption, and a major issue in a small subset of patients is 
severe hypomagnesaemia39. If the latter occurs it is typically a drug class effect, 
likely due to inhibition of cation transport in the colon.  
 
PPIs are now well recognised as a cause of acute interstitial nephritis, which, in a 
nested case-control study of 572,661 patients, occurred with an odds ratio of 
5.16 (translating into an incidence of 11.98 per 100,000 person-years)40. Early 
recognition and drug discontinuation are crucial for maximising renal recovery. 
There have also been a number of reports of PPIs triggering subacute cutaneous 
lupus erythematosus41. 
 
Finally, increased rates of chronic kidney disease and myocardial infarction have 
recently been reported among PPI users. In one study of 173,321 people, the 
hazard ratio of developing chronic renal impairment was 1.22, rising with 
increasing duration of exposure42. In a further data-mining exercise examining 
records from 2.9 million patients, PPIs were associated with a 1.16-fold risk of 
myocardial infarction, and a 2-fold increased risk of cardiovascular mortality43. 
The cause was not ascertained, and although the authors speculated about 
interference with nitric oxide signalling, an alternative explanation would be 
confounding due to increased use of acid suppression in patients with greater 
numbers of comorbidities and polypharmacy (and hence overall cardiovascular 
risk). 
   
Drug interactions 
The extensive, long-term use of PPIs in patients with multiple comorbidities and 
polypharmacy renders them high risk for drug-drug interactions. Specifically, 
their alteration of pH in the gastrointestinal tract can impact on drug absorption, 
and they inhibit (to varying degrees) cytochrome (CYP) p450 and the p-
glycoprotein pathway44. This may be a particular issue for omeprazole, which 
has high affinity for CYP2C19 and moderate affinity for CYP3A445. 
 
Drug interactions were raised as a major concern in the case of clopidogrel, 
which requires CYP2C19 for conversion to its active metabolite. An initial 
randomised controlled trial of 140 patients found a reduction in the platelet 
reactivity index after one week in patients receiving clopidogrel with 
omeprazole46, and on this basis a number of regulatory agencies counselled that 
both omeprazole and esomeprazole should be avoided in this context. The 
clinical relevance of the interaction has, however, been called into question, with 
the prospective COGENT trial reporting no increase in cardiovascular events in 
3,761 patients on omeprazole and dual antiplatelet therapy47. The trial was 
terminated prematurely due to lack of funding but, while this did restrict 
statistical power, a subsequent review concluded that, with all currently 
available clinical data, despite evidence of an ex vivo interaction, the case for 
adverse impact in patients in vivo had not been made48.  
 
Others have also highlighted the significant risk of bias in many of the 
retrospective studies reporting harmful interactions between PPIs and 
clopidogrel49, and pointed out that concomitant use does halve the risk of 
gastrointestinal bleeding50. Consequently, some authorities advocate preferential 
use of alternative PPIs with lower CYP2C19 affinity (such as pantoprazole or 
rabeprazole) in this patient cohort, although this strategy has not been subject to 
well-designed clinical trials.  
 
Although studies on drug interactions have been dominated by those focusing on 
antiplatelet therapies, PPIs can also decrease plasma concentrations of several 
anti-retroviral agents, dabigatran, mycophenolate mofetil, and targeted 
oncological signal pathway inhibitors, as well as increase the concentrations of 
calcineurin inhibitors, methotrexate and metformin51. As with clopidogrel, little 
evidence has emerged to date that these result in clinically meaningful harm, 
although it would still be prudent to take care when prescribing PPIs with drugs 
that have potential for an interaction to occur.  
 
Minimising overprescribing 
The steps required to curb and subsequently reduce inappropriate prescribing 
include: recognition of the problem; use of alternative approaches to manage 
conditions currently treated “by default” with PPIs; education regarding 
appropriate indications and durations for their use; and enhanced drug 
stewardship akin to that employed widely for antimicrobials, mandating better 
documentation around PPI prescriptions and regular review. Patient 
involvement and shared decision-making are also key52.   
 
One of the most frequent reasons for long-term PPI prescribing is dyspepsia. 
This is a condition that can often be significantly ameliorated by lifestyle 
modification or medication rationalisation3. Weight loss (if overweight) and 
smoking cessation should be strongly encouraged. Possible drug contributors to 
dyspepsia include calcium channel blockers, nitrates, theophyllines, 
bisphosphonates, antiplatelet agents and NSAIDs, and a therapeutics review 
should be conducted to consider whether these are still indicated or could be 
appropriately substituted. Where PPIs are prescribed, the lowest effective dose 
should be used, for the shortest possible duration. Low-cost PPIs should 
generally be used in preference to more expensive agents, although whether this 
extends to situations where drug-drug interactions could occur remains an open 
question. The indications and intended durations should be clearly documented 
and communicated to the primary care provider and pharmacy.  
 
Patients on long-term therapy should be reviewed on (at minimum) an annual 
basis and, if the indication for treatment was dyspepsia, encouraged to step-
down therapy gradually, aiming for the lowest effective dose. Substitution of 
PPIs with antacid or alginate therapy, or H2 receptor antagonists, can also be 
considered. Patients should be counselled regarding rebound acid secretion on 
drug discontinuation, that this does not necessarily represent recurrence of 
disease, and on strategies to manage this (preferably without re-escalating PPI 
dose)28.  
 
The other common rationale for long-term PPI prescribing is prophylaxis when 
receiving antiplatelet agents or NSAIDs. Most guidelines suggest this is only 
required for high-risk patients, specifically those over 65 years of age, with a 
history of peptic ulcer disease or upper gastrointestinal haemorrhage, or taking 
multiple medicines that augment gastrointestinal adverse effects53,54. The latter 
include high-dose steroids (dose equivalent greater than 30mg 
prednisolone/day), anticoagulants, and selective serotonin reuptake inhibitors.  
 
Time to deprescribe 
Prescribing of PPIs has skyrocketed over the past decade. These drugs can be 
effective, but are principally intended for short-term use yet often not 
discontinued. There is clear and consistent evidence of overprescribing as 
clinicians overestimate benefits and underestimate harms, associated with 
substantial costs to healthcare providers. Measures should be put in place to 
educate prescribers as to appropriate indications and durations for PPI use, 
provide a degree of stewardship, and facilitate long-term users in de-escalating 
therapy.  
 
Daniel J B Marks is a clinical pharmacologist at University College London 
Hospital and a postdoctoral research fellow at the Centre for Molecular Medicine, 
University College London 
 
References: 
1. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 
2008; 336(7634): 2-3. 10.1136/bmj.39406.449456.BE 
http://www.ncbi.nlm.nih.gov/pubmed/18174564. 
2. Dworzynski K, Pollit V, Kelsey A, Higgins B, Palmer K, Guideline 
Development G. Management of acute upper gastrointestinal bleeding: 
summary of NICE guidance. BMJ 2012; 344: e3412. 10.1136/bmj.e3412 
http://www.ncbi.nlm.nih.gov/pubmed/22695897. 
3. Ford AC, Moayyedi P. Dyspepsia. BMJ 2013; 347: f5059. 
10.1136/bmj.f5059 http://www.ncbi.nlm.nih.gov/pubmed/23990632. 
4. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of 
increasing antibiotic resistance. Gut 2010; 59(8): 1143-53. 
10.1136/gut.2009.192757 
http://www.ncbi.nlm.nih.gov/pubmed/20525969. 
5. Laine L. GI risk and risk factors of NSAIDs. J Cardiovasc Pharmacol 2006; 47 
Suppl 1: S60-6.  http://www.ncbi.nlm.nih.gov/pubmed/16785831. 
6. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of 
Gastroenterology guidelines on the diagnosis and management of Barrett's 
oesophagus. Gut 2014; 63(1): 7-42. 10.1136/gutjnl-2013-305372 
http://www.ncbi.nlm.nih.gov/pubmed/24165758. 
7. Neumann I, Letelier LM, Rada G, et al. Comparison of different regimens of 
proton pump inhibitors for acute peptic ulcer bleeding. Cochrane Database 
Syst Rev 2013; (6): CD007999. 10.1002/14651858.CD007999.pub2 
http://www.ncbi.nlm.nih.gov/pubmed/23760821. 
8. Hollingworth S, Duncan EL, Martin JH. Marked increase in proton pump 
inhibitors use in Australia. Pharmacoepidemiol Drug Saf 2010; 19(10): 
1019-24. 10.1002/pds.1969 
http://www.ncbi.nlm.nih.gov/pubmed/20623646. 
9. Haastrup P, Paulsen MS, Zwisler JE, et al. Rapidly increasing prescribing of 
proton pump inhibitors in primary care despite interventions: a 
nationwide observational study. Eur J Gen Pract 2014; 20(4): 290-3. 
10.3109/13814788.2014.905535 
http://www.ncbi.nlm.nih.gov/pubmed/24779533. 
10. McGowan B, Bennett K, Barry M, Canny M. The utilisation and expenditure 
of medicines for the prophylaxis and treatment of osteoporosis. Ir Med J 
2008; 101(2): 38-41.  http://www.ncbi.nlm.nih.gov/pubmed/18450246. 
11. Ribolsi M, Savarino E, De Bortoli N, et al. Reflux pattern and role of 
impedance-pH variables in predicting PPI response in patients with 
suspected GERD-related chronic cough. Aliment Pharmacol Ther 2014; 
40(8): 966-73. 10.1111/apt.12919 
http://www.ncbi.nlm.nih.gov/pubmed/25109844. 
12. Schepisi R, Fusco S, Sganga F, et al. Inappropriate Use of Proton Pump 
Inhibitors in Elderly Patients Discharged from Acute Care Hospitals. J Nutr 
Health Aging 2016; 20(6): 665-70. 10.1007/s12603-015-0642-5 
http://www.ncbi.nlm.nih.gov/pubmed/27273358. 
13. Haastrup PF, Rasmussen S, Hansen JM, Christensen RD, Sondergaard J, 
Jarbol DE. General practice variation when initiating long-term prescribing 
of proton pump inhibitors: a nationwide cohort study. BMC Fam Pract 
2016; 17(1): 57. 10.1186/s12875-016-0460-9 
http://www.ncbi.nlm.nih.gov/pubmed/27233634. 
14. Haastrup PF, Paulsen MS, Christensen RD, Sondergaard J, Hansen JM, Jarbol 
DE. Medical and non-medical predictors of initiating long-term use of 
proton pump inhibitors: a nationwide cohort study of first-time users 
during a 10-year period. Aliment Pharmacol Ther 2016; 44(1): 78-87. 
10.1111/apt.13649 http://www.ncbi.nlm.nih.gov/pubmed/27137875. 
15. van den Bemt PM, Chaaouit N, van Lieshout EM, Verhofstad MH. 
Noncompliance with guidelines on proton pump inhibitor prescription as 
gastroprotection in hospitalized surgical patients who are prescribed 
NSAIDs. Eur J Gastroenterol Hepatol 2016. 
10.1097/MEG.0000000000000634 
http://www.ncbi.nlm.nih.gov/pubmed/27046006. 
16. Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL. Inappropriate 
prescribing of proton pump inhibitors in primary care. Postgrad Med J 
2007; 83(975): 66-8. 10.1136/pgmj.2006.051151 
http://www.ncbi.nlm.nih.gov/pubmed/17267683. 
17. Jarchow-Macdonald AA, Mangoni AA. Prescribing patterns of proton pump 
inhibitors in older hospitalized patients in a Scottish health board. Geriatr 
Gerontol Int 2013; 13(4): 1002-9. 10.1111/ggi.12047 
http://www.ncbi.nlm.nih.gov/pubmed/23506515. 
18. Pasina L, Nobili A, Tettamanti M, et al. Prevalence and appropriateness of 
drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in 
a cohort of hospitalized elderly. Eur J Intern Med 2011; 22(2): 205-10. 
10.1016/j.ejim.2010.11.009 
http://www.ncbi.nlm.nih.gov/pubmed/21402255. 
19. George CJ, Korc B, Ross JS. Appropriate proton pump inhibitor use among 
older adults: a retrospective chart review. Am J Geriatr Pharmacother 2008; 
6(5): 249-54. 10.1016/j.amjopharm.2008.12.001 
http://www.ncbi.nlm.nih.gov/pubmed/19161927. 
20. Pohland CJ, Scavnicky SA, Lasky SS, Good CB. Lansoprazole overutilization: 
methods for step-down therapy. Am J Manag Care 2003; 9(5): 353-8.  
http://www.ncbi.nlm.nih.gov/pubmed/12744297. 
21. Thomas L, Culley EJ, Gladowski P, Goff V, Fong J, Marche SM. Longitudinal 
analysis of the costs associated with inpatient initiation and subsequent 
outpatient continuation of proton pump inhibitor therapy for stress ulcer 
prophylaxis in a large managed care organization. J Manag Care Pharm 
2010; 16(2): 122-9. 10.18553/jmcp.2010.16.2.122 
http://www.ncbi.nlm.nih.gov/pubmed/20178397. 
22. Van Soest EM, Siersema PD, Dieleman JP, Sturkenboom MC, Kuipers EJ. 
Persistence and adherence to proton pump inhibitors in daily clinical 
practice. Aliment Pharmacol Ther 2006; 24(2): 377-85. 10.1111/j.1365-
2036.2006.02982.x http://www.ncbi.nlm.nih.gov/pubmed/16842465. 
23. van Vliet EP, Otten HJ, Rudolphus A, et al. Inappropriate prescription of 
proton pump inhibitors on two pulmonary medicine wards. Eur J 
Gastroenterol Hepatol 2008; 20(7): 608-12. 
10.1097/MEG.0b013e3282f52f95 
http://www.ncbi.nlm.nih.gov/pubmed/18679061. 
24. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Magnitude and economic effect of 
overuse of antisecretory therapy in the ambulatory care setting. Am J 
Manag Care 2010; 16(9): e228-34.  
http://www.ncbi.nlm.nih.gov/pubmed/21250399. 
25. van Vliet EP, Steyerberg EW, Otten HJ, et al. The effects of guideline 
implementation for proton pump inhibitor prescription on two pulmonary 
medicine wards. Aliment Pharmacol Ther 2009; 29(2): 213-21. 
10.1111/j.1365-2036.2008.03875.x 
http://www.ncbi.nlm.nih.gov/pubmed/19006542. 
26. Walker NM, McDonald J. An evaluation of the use of proton pump 
inhibitors. Pharm World Sci 2001; 23(3): 116-7.  
http://www.ncbi.nlm.nih.gov/pubmed/11468876. 
27. Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and 
enablers to minimising potentially inappropriate medications in adults: a 
systematic review and thematic synthesis. BMJ Open 2014; 4(12): e006544. 
10.1136/bmjopen-2014-006544 
http://www.ncbi.nlm.nih.gov/pubmed/25488097. 
28. Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor 
therapy induces acid-related symptoms in healthy volunteers after 
withdrawal of therapy. Gastroenterology 2009; 137(1): 80-7, 7 e1. 
10.1053/j.gastro.2009.03.058 
http://www.ncbi.nlm.nih.gov/pubmed/19362552. 
29. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-
associated diarrhea and proton pump inhibitor therapy: a meta-analysis. 
Am J Gastroenterol 2012; 107(7): 1001-10. 10.1038/ajg.2012.179 
http://www.ncbi.nlm.nih.gov/pubmed/22710578. 
30. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric 
infection in patients taking acid suppression. Am J Gastroenterol 2007; 
102(9): 2047-56; quiz 57. 10.1111/j.1572-0241.2007.01275.x 
http://www.ncbi.nlm.nih.gov/pubmed/17509031. 
31. Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the 
gut microbiome. Gut 2016; 65(5): 740-8. 10.1136/gutjnl-2015-310376 
http://www.ncbi.nlm.nih.gov/pubmed/26657899. 
32. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive 
drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 
2011; 183(3): 310-9. 10.1503/cmaj.092129 
http://www.ncbi.nlm.nih.gov/pubmed/21173070. 
33. Filion KB, Chateau D, Targownik LE, et al. Proton pump inhibitors and the 
risk of hospitalisation for community-acquired pneumonia: replicated 
cohort studies with meta-analysis. Gut 2014; 63(4): 552-8. 10.1136/gutjnl-
2013-304738 http://www.ncbi.nlm.nih.gov/pubmed/23856153. 
34. Khalili H, Huang ES, Jacobson BC, Camargo CA, Jr., Feskanich D, Chan AT. 
Use of proton pump inhibitors and risk of hip fracture in relation to dietary 
and lifestyle factors: a prospective cohort study. BMJ 2012; 344: e372. 
10.1136/bmj.e372 http://www.ncbi.nlm.nih.gov/pubmed/22294756. 
35. Graziani G, Como G, Badalamenti S, et al. Effect of gastric acid secretion on 
intestinal phosphate and calcium absorption in normal subjects. Nephrol 
Dial Transplant 1995; 10(8): 1376-80.  
http://www.ncbi.nlm.nih.gov/pubmed/8538929. 
36. Costa-Rodrigues J, Reis S, Teixeira S, Lopes S, Fernandes MH. Dose-
dependent inhibitory effects of proton pump inhibitors on human 
osteoclastic and osteoblastic cell activity. FEBS J 2013; 280(20): 5052-64. 
10.1111/febs.12478 http://www.ncbi.nlm.nih.gov/pubmed/23937530. 
37. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J 
Gastroenterol 2009; 104 Suppl 2: S5-9. 10.1038/ajg.2009.45 
http://www.ncbi.nlm.nih.gov/pubmed/19262546. 
38. Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and 
histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 
2013; 310(22): 2435-42. 10.1001/jama.2013.280490 
http://www.ncbi.nlm.nih.gov/pubmed/24327038. 
39. Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: 
hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol 
Ther 2012; 36(5): 405-13. 10.1111/j.1365-2036.2012.05201.x 
http://www.ncbi.nlm.nih.gov/pubmed/22762246. 
40. Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case-control 
study indicates an increased risk of acute interstitial nephritis with proton 
pump inhibitor use. Kidney Int 2014; 86(4): 837-44. 10.1038/ki.2014.74 
http://www.ncbi.nlm.nih.gov/pubmed/24646856. 
41. Sandholdt LH, Laurinaviciene R, Bygum A. Proton pump inhibitor-induced 
subacute cutaneous lupus erythematosus. Br J Dermatol 2014; 170(2): 
342-51. 10.1111/bjd.12699 
http://www.ncbi.nlm.nih.gov/pubmed/24547721. 
42. Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton Pump 
Inhibitors and Risk of Incident CKD and Progression to ESRD. J Am Soc 
Nephrol 2016. 10.1681/ASN.2015121377 
http://www.ncbi.nlm.nih.gov/pubmed/27080976. 
43. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton Pump Inhibitor Usage 
and the Risk of Myocardial Infarction in the General Population. PLoS One 
2015; 10(6): e0124653. 10.1371/journal.pone.0124653 
http://www.ncbi.nlm.nih.gov/pubmed/26061035. 
44. Polasek TM, Lin FP, Miners JO, Doogue MP. Perpetrators of 
pharmacokinetic drug-drug interactions arising from altered cytochrome 
P450 activity: a criteria-based assessment. Br J Clin Pharmacol 2011; 71(5): 
727-36. 10.1111/j.1365-2125.2011.03903.x 
http://www.ncbi.nlm.nih.gov/pubmed/21223357. 
45. Li W, Zeng S, Yu LS, Zhou Q. Pharmacokinetic drug interaction profile of 
omeprazole with adverse consequences and clinical risk management. Ther 
Clin Risk Manag 2013; 9: 259-71. 10.2147/TCRM.S43151 
http://www.ncbi.nlm.nih.gov/pubmed/23745048. 
46. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the 
antiplatelet action of clopidogrel associated with aspirin: the randomized, 
double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll 
Cardiol 2008; 51(3): 256-60. 10.1016/j.jacc.2007.06.064 
http://www.ncbi.nlm.nih.gov/pubmed/18206732. 
47. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without 
omeprazole in coronary artery disease. N Engl J Med 2010; 363(20): 1909-
17. 10.1056/NEJMoa1007964 
http://www.ncbi.nlm.nih.gov/pubmed/20925534. 
48. Focks JJ, Brouwer MA, van Oijen MG, Lanas A, Bhatt DL, Verheugt FW. 
Concomitant use of clopidogrel and proton pump inhibitors: impact on 
platelet function and clinical outcome- a systematic review. Heart 2013; 
99(8): 520-7. 10.1136/heartjnl-2012-302371 
http://www.ncbi.nlm.nih.gov/pubmed/22851683. 
49. Lima JP, Brophy JM. The potential interaction between clopidogrel and 
proton pump inhibitors: a systematic review. BMC Med 2010; 8: 81. 
10.1186/1741-7015-8-81 
http://www.ncbi.nlm.nih.gov/pubmed/21134261. 
50. Siller-Matula JM, Jilma B, Schror K, Christ G, Huber K. Effect of proton pump 
inhibitors on clinical outcome in patients treated with clopidogrel: a 
systematic review and meta-analysis. J Thromb Haemost 2010; 8(12): 
2624-41. 10.1111/j.1538-7836.2010.04049.x 
http://www.ncbi.nlm.nih.gov/pubmed/20831618. 
51. Yucel E, Sancar M, Yucel A, Okuyan B. Adverse drug reactions due to drug-
drug interactions with proton pump inhibitors: assessment of systematic 
reviews with AMSTAR method. Expert Opin Drug Saf 2016; 15(2): 223-36. 
10.1517/14740338.2016.1128413 
http://www.ncbi.nlm.nih.gov/pubmed/26635063. 
52. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Review of 
deprescribing processes and development of an evidence-based, patient-
centred deprescribing process. Br J Clin Pharmacol 2014; 78(4): 738-47. 
10.1111/bcp.12386 http://www.ncbi.nlm.nih.gov/pubmed/24661192. 
53. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert 
consensus document on reducing the gastrointestinal risks of antiplatelet 
therapy and NSAID use. Am J Gastroenterol 2008; 103(11): 2890-907. 
10.1111/j.1572-0241.2008.02216.x 
http://www.ncbi.nlm.nih.gov/pubmed/18853965. 
54. Lanza FL, Chan FK, Quigley EM, Practice Parameters Committee of the 
American College of G. Guidelines for prevention of NSAID-related ulcer 
complications. Am J Gastroenterol 2009; 104(3): 728-38. 
10.1038/ajg.2009.115 http://www.ncbi.nlm.nih.gov/pubmed/19240698. 
 
